Sanofi Reports Strong Q3 2026 Results Driven by Dupixent and Upgraded Full-Year Guidance
Sanofi (SNY) reported robust third-quarter 2026 financial results, with net sales reaching €14.4 billion, a 14.3% increase at constant exchange rates. Growth was primarily fueled by the immunology portfolio, specifically Dupixent, which saw sales surge 34.8% to €5.7 billion. The company also noted significant momentum from new pharmaceutical launches and improved operating margins due to disciplined cost management. Following these strong results, Sanofi upgraded its full-year guidance for both sales (13% to 15% growth) and business EPS (15% to 17% growth). While the company faces some headwinds, such as a decline in vaccine sales and anticipated pricing shifts in 2027, strategic moves like the Regeneron alliance expansion and the Cheplapharm partnership aim to bolster long-term pipeline development and portfolio optimization.
Topics: earnings report EPS increase guidance upgrade pharmaceutical sales revenue growth